title: Acute erythroleukemia with der(1;7)(q10;p10) as a sole acquired abnormality after treatment with azathioprine.
authors.forename: Tae Sung
authors.initials: TS
authors.lastname: Park
authors.forename: June-Won
authors.initials: JW
authors.lastname: Cheong
authors.forename: Jaewoo
authors.initials: J
authors.lastname: Song
authors.forename: Kyung-A
authors.initials: KA
authors.lastname: Lee
authors.forename: Sang-Guk
authors.initials: SG
authors.lastname: Lee
authors.forename: Juwon
authors.initials: J
authors.lastname: Kim
authors.forename: Seoyoung
authors.initials: S
authors.lastname: Yoon
authors.forename: Jong Rak
authors.initials: JR
authors.lastname: Choi
authors.forename: Rojin
authors.initials: R
authors.lastname: Park
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001379:Azathioprine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D002878:Chromosomes, Human, Pair 1 / Q000235:genetics / Q000648:ultrastructure*; D002897:Chromosomes, Human, Pair 7 / Q000235:genetics / Q000648:ultrastructure*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy*; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D004915:Leukemia, Erythroblastic, Acute / Q000139:chemically induced* / Q000188:drug therapy; D008875:Middle Aged; D009503:Neutropenia / Q000209:etiology; D012772:Shock, Septic / Q000209:etiology
chemical_list: D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D001379:Azathioprine